Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)
China · Delayed Price · Currency is CNY 15.93
+0.23 (1.46%)
Feb 3, 2026, 2:55 PM CST
SHE:002755 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,790 | 1,741 | 1,430 | 1,859 | 3,041 | 3,719 |
Other Revenue | 37.05 | 37.05 | 13.77 | 13.61 | 65.22 | 63.37 |
| 1,827 | 1,778 | 1,443 | 1,873 | 3,107 | 3,783 | |
Revenue Growth (YoY) | 6.96% | 23.15% | -22.92% | -39.72% | -17.87% | -16.29% |
Cost of Revenue | 371.59 | 333.53 | 277.51 | 245.7 | 277.05 | 311.44 |
Gross Profit | 1,455 | 1,444 | 1,166 | 1,627 | 2,830 | 3,471 |
Selling, General & Admin | 1,121 | 1,151 | 973.24 | 1,333 | 2,159 | 2,439 |
Research & Development | 126.96 | 177.32 | 472.01 | 588.84 | 324.45 | 255.89 |
Other Operating Expenses | 2.72 | 21.83 | 15.67 | 24.89 | 41.19 | 51.99 |
Operating Expenses | 1,252 | 1,350 | 1,456 | 1,940 | 2,520 | 2,739 |
Operating Income | 203.57 | 94.55 | -290.49 | -313.2 | 309.73 | 732.55 |
Interest Expense | -2.11 | -2.64 | -2.81 | -2.76 | -3.99 | -2.96 |
Interest & Investment Income | 18.5 | 30.99 | 26.78 | 39.89 | 43.72 | 36.58 |
Currency Exchange Gain (Loss) | 1.37 | 1.37 | 0.96 | 0.07 | -0.02 | -0.06 |
Other Non Operating Income (Expenses) | 2.75 | -1.8 | -3.19 | -1.89 | -0.08 | -1.77 |
EBT Excluding Unusual Items | 224.08 | 122.46 | -268.75 | -277.89 | 349.36 | 764.35 |
Gain (Loss) on Sale of Investments | 3.72 | 12.73 | 12.5 | 1.68 | 2.39 | - |
Gain (Loss) on Sale of Assets | 0 | -0.03 | 0.03 | 0.21 | 0.3 | -0.02 |
Asset Writedown | -5.77 | -3.06 | -5.7 | -20.79 | -0.86 | -0.26 |
Other Unusual Items | 19.35 | 19.35 | 60.99 | 34.29 | 54.87 | 57.14 |
Pretax Income | 241.39 | 151.45 | -200.93 | -262.5 | 406.07 | 821.2 |
Income Tax Expense | 14.96 | 22.98 | 6.55 | 3.7 | 25.51 | 95.83 |
Earnings From Continuing Operations | 226.43 | 128.47 | -207.48 | -266.21 | 380.56 | 725.37 |
Minority Interest in Earnings | 30.16 | 31.82 | 58.95 | 40.38 | -0.66 | -3.74 |
Net Income | 256.59 | 160.29 | -148.53 | -225.83 | 379.91 | 721.63 |
Net Income to Common | 256.59 | 160.29 | -148.53 | -225.83 | 379.91 | 721.63 |
Net Income Growth | 57.28% | - | - | - | -47.35% | -7.60% |
Shares Outstanding (Basic) | 960 | 943 | 928 | 941 | 927 | 925 |
Shares Outstanding (Diluted) | 960 | 943 | 928 | 941 | 927 | 925 |
Shares Change (YoY) | 4.80% | 1.57% | -1.34% | 1.55% | 0.16% | -0.49% |
EPS (Basic) | 0.27 | 0.17 | -0.16 | -0.24 | 0.41 | 0.78 |
EPS (Diluted) | 0.27 | 0.17 | -0.16 | -0.24 | 0.41 | 0.78 |
EPS Growth | 50.07% | - | - | - | -47.44% | -7.14% |
Free Cash Flow | 261.3 | 180.94 | -155.89 | -203.27 | 433.95 | 380.7 |
Free Cash Flow Per Share | 0.27 | 0.19 | -0.17 | -0.22 | 0.47 | 0.41 |
Dividend Per Share | 0.120 | 0.120 | - | - | 0.100 | 0.200 |
Dividend Growth | - | - | - | - | -50.00% | -9.09% |
Gross Margin | 79.66% | 81.24% | 80.77% | 86.88% | 91.08% | 91.77% |
Operating Margin | 11.14% | 5.32% | -20.13% | -16.73% | 9.97% | 19.37% |
Profit Margin | 14.04% | 9.02% | -10.29% | -12.06% | 12.23% | 19.08% |
Free Cash Flow Margin | 14.30% | 10.18% | -10.80% | -10.85% | 13.97% | 10.06% |
EBITDA | 274.07 | 169.84 | -208.79 | -224.03 | 401.33 | 825.17 |
EBITDA Margin | 15.00% | 9.55% | -14.46% | -11.96% | 12.92% | 21.81% |
D&A For EBITDA | 70.5 | 75.3 | 81.7 | 89.17 | 91.6 | 92.62 |
EBIT | 203.57 | 94.55 | -290.49 | -313.2 | 309.73 | 732.55 |
EBIT Margin | 11.14% | 5.32% | -20.12% | -16.73% | 9.97% | 19.37% |
Effective Tax Rate | 6.20% | 15.17% | - | - | 6.28% | 11.67% |
Revenue as Reported | 1,827 | 1,778 | 1,443 | 1,873 | 3,107 | 3,783 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.